The Association between Helicobacter pylori and Colorectal Neoplasia.
Cancer screening
Colorectal neoplasms
Helicobacter pylori
Metabolic syndrome
Journal
Medical principles and practice : international journal of the Kuwait University, Health Science Centre
ISSN: 1423-0151
Titre abrégé: Med Princ Pract
Pays: Switzerland
ID NLM: 8901334
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
07
2022
accepted:
11
12
2022
medline:
5
6
2023
pubmed:
30
12
2022
entrez:
29
12
2022
Statut:
ppublish
Résumé
Helicobacter pylori (H. pylori) and colorectal neoplasia (CRN) are frequent entities. Epidemiological data suggest an association between H. pylori positivity (H. pylori +) and CRN, whereas pathophysiologic considerations substantiate a possible causal relationship. However, the relationship between CRN and H. pylori + may also be mediated by shared risk factors. Therefore, the aim of this cross-sectional study was to evaluate a possible independent relationship between H. pylori and CRN in a Central European cohort. We included 5,707 asymptomatic patients. All patients underwent screening colonoscopy and upper gastrointestinal endoscopy. We assessed the association between any CRN and advanced CRN with H. pylori + using multilevel logistic regression. We adjusted for age, sex, a positive family history of colorectal cancer, and cardiovascular risk. 1,082 patients (19%) were H. pylori + and 4,625 (81%) H. pylori -. Patients with both CRN and H. pylori had more cardiometabolic risk factors. In univariate (aOR 1.20; 1.10-1.31) and multivariable analysis (aOR 1.20; 1.08-1.32), H. pylori + was associated with the diagnosis of any CRN. However, H. pylori + was associated with the presence of advanced CRN (aOR 1.26; 0.96-1.64) only in trend. We found a clustered co-occurrence of CRN and H. pylori. This association persisted after correction for shared cardiometabolic risk factors. We suggest that our analysis emphasizes the clinical value of H. pylori eradication. Whether "test and treat" H. pylori is warranted to prevent CRN remains unclear but is at least a possibility given the simplicity of "test and treat."
Identifiants
pubmed: 36580903
pii: 000528794
doi: 10.1159/000528794
pmc: PMC10267487
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-85Informations de copyright
© 2022 The Author(s). Published by S. Karger AG, Basel.
Références
BMC Infect Dis. 2018 Jun 15;18(1):278
pubmed: 29907086
Am J Gastroenterol. 2017 Feb;112(2):212-239
pubmed: 28071659
N Engl J Med. 2019 Mar 21;380(12):1158-1165
pubmed: 30893536
Sci Rep. 2021 Sep 7;11(1):17785
pubmed: 34493755
Digestion. 1999;60(3):210-5
pubmed: 10343134
Int J Colorectal Dis. 2020 Jun;35(6):985-995
pubmed: 32314192
Cancer Causes Control. 2012 Jun;23(6):897-906
pubmed: 22527167
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
Int J Colorectal Dis. 2001 Aug;16(4):202-10
pubmed: 11515678
Dig Dis Sci. 2014 Aug;59(8):1698-709
pubmed: 24563236
BMC Cancer. 2014 Apr 28;14:296
pubmed: 24774100
J Glob Infect Dis. 2013 Apr;5(2):60-7
pubmed: 23853433
Front Med (Lausanne). 2022 Jan 18;8:706036
pubmed: 35118081
J Gastrointest Oncol. 2014 Dec;5(6):463-8
pubmed: 25436126
Eur Heart J. 2021 Jul 1;42(25):2439-2454
pubmed: 34120177
Gut. 2020 Dec;69(12):2093-2112
pubmed: 33004546
World J Surg Oncol. 2007 May 12;5:51
pubmed: 17498313
Am J Gastroenterol. 2021 Mar 1;116(3):458-479
pubmed: 33657038
Colorectal Dis. 2020 Jul;22(7):814-817
pubmed: 31953982
J Med Microbiol. 2005 Nov;54(Pt 11):1031-1035
pubmed: 16192433
World J Gastroenterol. 2016 Jan 14;22(2):649-58
pubmed: 26811614
Oncotarget. 2015 Aug 7;6(22):19017-26
pubmed: 26158864
Mol Cell. 2014 Apr 24;54(2):309-20
pubmed: 24766895
Lancet Glob Health. 2019 Oct;7(10):e1332-e1345
pubmed: 31488387
Am J Gastroenterol. 2001 Jan;96(1):84-8
pubmed: 11197293
Gut. 2022 Aug 8;:
pubmed: 35944925
World J Gastrointest Oncol. 2020 May 15;12(5):582-591
pubmed: 32461789
Minerva Med. 2022 Dec;113(6):936-949
pubmed: 35384436
Ann Transl Med. 2015 Jan;3(1):10
pubmed: 25705642